Abreu Brain Therapeutics

Abreu Brain Therapeutics is a clinical-stage biotechnology company focused on treating neurodegenerative diseases through a proprietary thermal modulation platform. The company's core technology is based on the discovery of the Abreu Brain Thermal Tunnel (ABTT), which allows for non-invasive, direct access to the brain's thermoregulatory center. By applying precise thermal energy, the company aims to induce heat shock proteins and enhance the clearance of misfolded proteins associated with Alzheimer's and Parkinson's diseases. Their lead program is currently in Phase 2 clinical trials for the treatment of Alzheimer's disease. Abreu Brain Therapeutics represents a novel intersection of medical device technology and biological protein management.